New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 9, 2012
08:41 EDTAVNR, IPXLAvanir sues Impax over planned Nuedexta generic, Bloomberg reports
Avanir Pharmaceuticals (AVNR) is suing Impax Laboratories (IPXL) for allegedly infringing a new patent for the drug Nuedexta and planning to market a generic version of the drug before the patent expires in 2023, reported Bloomberg, citing a complaint filed in a federal court in Delaware. Reference Link
News For AVNR;IPXL From The Last 14 Days
Check below for free stories on AVNR;IPXL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 21, 2014
09:18 EDTAVNRFDA accepts Avanir's IND application for Phase II study for AVP-786
Subscribe for More Information
July 16, 2014
11:35 EDTIPXLLannett announces inquiry received from Connecticut Attorney General
Subscribe for More Information
09:13 EDTAVNRAvanir's Nuedexta shows positive early results in clinical study of Alzheimer's
Subscribe for More Information
09:11 EDTIPXLLannett risk has increased on competitor probe, says Roth Capital
Subscribe for More Information
July 15, 2014
17:10 EDTIPXLImpax receives subpoena related to digoxin sales
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use